Class / Patent application number | Description | Number of patent applications / Date published |
544229000 | Boron or silicon containing | 38 |
20090143578 | Process for Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation - Processes for preparing entecavir and novel intermediates thereof using carbon-silicon oxidation. | 06-04-2009 |
20090221818 | Inhibitors of Fibroblast Activation Protein Alpha - Disclosed are peptide-based compounds that include boronic acid or cyano functionality, which efficiently and selectively inhibit fibroblast activation protein alpha. Among other therapeutic utilities, the peptide-based compounds may be useful for the treatment of cancer. | 09-03-2009 |
20090221819 | FLUORESCENT COMPOUNDS AND USE OF SAID COMPOUNDS IN MULTIPHOTON METHODS OR DEVICES - The invention relates to a chemical compound with an effective double photon absorbance section of greater than 50 GM, preferably greater than 100 GM, for at least one wavelength in the range 700-1200 nm, characterised in being made up of a core with double photon absorption properties connected by separate covalent bonds to at least two boron dipyrromethene type emitters of formula (—BDP) (I): where one of R | 09-03-2009 |
20090253908 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS - Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | 10-08-2009 |
20100174072 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS - The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib. | 07-08-2010 |
20100197910 | PROCESS FOR PREPARATION OF PRULIFLOXACIN USING NOVEL INTERMEDIATES - The present invention provides a novel process for the preparation of the prulifloxacin intermediate, 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-[1,3] thiazeto[3,2-a]quinoline-3-carboxylic acid, thereby producing prulifloxacin and its pharmaceutical acceptable acid addition salts thereof in high purity and in high yield using novel intermediates in lesser reaction time. Thus, for example, ethyl 6,7-difluoro-1-methyl-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate is reacted with boric acid in the presence of acetic anhydride and acetic acid to give a borane compound, which is then condensed with piperazine in the presence of acetonitrile and dimethylsulfoxide, followed by treatment with potassium hydroxide solution to give 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-[1,3] thiazeto [3,2-a]quinoline-3-carboxylic acid. | 08-05-2010 |
20100197911 | Nitrogen-Containing Aromatic Derivatives - Compounds represented by the following general formula: | 08-05-2010 |
20100311968 | DEPROTECTION OF BOC-PROTECTED COMPOUNDS - Organic compounds having t-butyl ester or BOC carbonate protecting groups are effectively deprotected by heating in a fluorinated alcohol solution. | 12-09-2010 |
20100317852 | AMINO-CONTAINING VINYLSILANE COMPOUNDS AND MAKING METHOD - Vinylsilane compounds having a specific amino group, typically diethylaminopropyldimethylvinylsilane, N-methylpiperazinylpropyldimethylvinylsilane, and bistrimethylsilylaminopropyldimethylvinylsilane are novel and useful as a modifier for polymers. | 12-16-2010 |
20110046372 | NOVEL BORON COMPOUNDS, THEIR PRODUCTION PROCESSES, AND FUNCTIONAL ELECTRONIC DEVICES USING SAME - The present invention provides novel boron compounds which are useful, depending on their characteristics, as light-emitting materials, electron-transport materials, electron-injection materials, hole-blocking materials, or organic semiconductor materials, and which have new molecular structures quite different from those of the heretofore known boron compounds; their production processes; and functional electronic devices using the same. The novel boron compounds are, for example, those of the following formula (1): | 02-24-2011 |
20110201806 | Methods for Forming Protected Organoboronic Acids - Described are methods of forming protected boronic acids that provide in a manner that is straightforward, scalable, and cost-effective a wide variety of building blocks, such as building blocks containing complex and/or pharmaceutically important structures, and/or provide simple or complex protected organoboronic acid building blocks. A first method includes reacting an imino-di-carboxylic acid and an organoboronate salt. A second method includes reacting a N-substituted morpholine dione and an organoboronic acid. | 08-18-2011 |
20110237793 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND - This invention is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions. | 09-29-2011 |
20120041196 | Proteasome Inhibitors and Methods of Using the Same - The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity. | 02-16-2012 |
20120136150 | 4-(3-Butynyl)Aminopyrimidine Derivatives as Pest Control Agents for Agricultural and Horticultural Use - Novel 4-(3-butynyl)aminopyrimidine derivatives represented by general formula [I] are useful as pest control agents. In general formula [I], R | 05-31-2012 |
20120178928 | ORGANIC ELECTROLUMINESCENCE DEVICE - An organic electroluminescence device includes: a pair of electrodes; and at least one organic layer including a light emitting layer, the light emitting layer being provided between the pair of electrodes, wherein at least one layer of the at least one organic layer contains a compound represented by formula (1): | 07-12-2012 |
20120289699 | Process for Preparing and Purifying Bortezomib - The present invention provides a synthetic process for producing bortezomib using a novel intermediate. The present invention also provides a process for purifying bortezomib anhydride, and a new crystalline polymorph of bortezomib anhydride. | 11-15-2012 |
20130005968 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS - The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib. | 01-03-2013 |
20130060026 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR - This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases. | 03-07-2013 |
20130085277 | PROCESS FOR THE PREPARATION OF BORTEZOMIB - The present invention relates to a process for the preparation of bortezomib (Formula I) and its intermediates. | 04-04-2013 |
20130085278 | METHODS FOR THE PREPARATION OF 5-[2-[7 (TRIFLUOROMETHYL)-5-[4- (TRIFLUOROMETHYL)PHENYL]PYRAZOLO [1,5-A]PYRIMIDIN-3-YL]ETHYNYL]-2-PYRIDINAMINE - The present invention provides methods for preparing 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]-2-pyridinamine (compound A), which is useful for the treatment of depression and other CNS disorders. The present methods are useful for preparing compound A on large scale in manufacturing facilities. | 04-04-2013 |
20130203988 | PROCESS FOR MAKING BORTEZOMIB AND INTERMEDIATES FOR THE PROCESS | 08-08-2013 |
20130253190 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS - The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases. | 09-26-2013 |
20130253191 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS - The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases. | 09-26-2013 |
20130345423 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT - A new method for the synthesis of L-Glutamyl-γ-D-Glutamic acid and its use in the synthesis of (2R)-((4S)-carboxy-4-(4,N-(((6S)-2-(hydroxymethyl)-4-oxo-3,4,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino)benzamido)butanamido)pentanedioic acid, 1 are provided. Also provided is an efficient method for the isolation and purification of the trisodium salt of the abovementioned acid, 2, in a form suitable for long term storage and use in a parenteral dosing form. | 12-26-2013 |
20140011998 | DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 01-09-2014 |
20140073785 | Methods for Forming Protected Organoboronic Acids - Described are methods of forming protected boronic acids that provide in a manner that is straightforward, scalable, and cost-effective a wide variety of building blocks, such as building blocks containing complex and/or pharmaceutically important structures, and/or provide simple or complex protected organoboronic acid building blocks. A first method includes reacting an imino-di-carboxylic acid and an organoboronate salt. A second method includes reacting a N-substituted morpholine dione and an organoboronic acid. | 03-13-2014 |
20140100367 | NOVEL COMPOUNDS FOR ORGANIC ELECTRONIC MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME - The present invention relates to a novel compound and an organic electroluminescent device containing the same. The compound according to the present invention can manufacture an organic electroluminescent device which has high luminous efficiency and a long operation lifetime. | 04-10-2014 |
20140114069 | NOVEL COMPOUNDS FOR ORGANIC ELECTRONIC MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME - The present invention relates to electroluminescent compounds of formula 1 where A and/or B represent fluorene, carbazole, dibenzo[b,d]thiophene or dibenzo[b,d]furan derivatives and L | 04-24-2014 |
20140357862 | SILYL-PROTECTED NITROGEN-CONTAINING CYCLIC COMPOUNDS AND MAKING METHOD - Silyl-protected nitrogen-containing cyclic compounds having formula (1) are provided wherein R | 12-04-2014 |
20150038706 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS - The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib. | 02-05-2015 |
20150105554 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER - The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof, as well as to key intermediates towards their synthesis. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer. | 04-16-2015 |
20150315149 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF - Methods are disclosed for the preparation of netupitant and pharmaceutically acceptable salts thereof which are novel, easily reproducible, environmentally safe and cost effective. The methods may employ inexpensive starting materials and the preparation processes for intermediates are simple and highly reproducible. Novel intermediates for the preparation of netupitant and pharmaceutically acceptable salts thereof are also disclosed. Amorphous netupitant and methods of making same are disclosed. | 11-05-2015 |
20150342191 | CYCLIC AZA-SILA COMPOUNDS AS INSECT REPELLANTS - The invention relates to aza-sila compounds of Formula (I), useful as insect repellants. wherein, ‘A’ is selected from the group consisting of branched or unbranched (C1-C12) alkyl, branched or unbranched (C1-C12) alkynyl; and substituted or unsubstituted 4 to 6 membered acyclic saturated or unsaturated compounds, wherein the substituents are selected from the group consisting of halogen, hydrogen, (C1-C6) alkyl, aryl, arylalkyl and heterocyclic; or ‘A’ is independently selected from the group consisting of the following moiety: Formula (II) wherein, X and Y are identical or different and independently selected from the group consisting of —C—, —N, —O, and —S; where R1, R2, R3, and R4 are identical or different and are independently selected from the group consisting of hydrogen, halogen, linear or branched (C1-C6) alkyl, aryl, arylalkyl, hydroxyl, and heterocyclic; and wherein, the halogen is selected from the group consisting of —Cl, —I, —Br, and —F. The invention further discloses a process for the preparation of the compounds of Formula (I). | 12-03-2015 |
20150344439 | Convenient Process for the Preparation of Statins - Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of statins. | 12-03-2015 |
20160016983 | New Modified Nucleic Acid - Provided is an oligonucleic acid analog which contains, as at least one structural unit thereof, a modified nucleic acid monomer compound which is a ring-open nucleoside having a cleaved carbon-carbon bond between the 2′ and 3′ positions and a substituent hydroxymethyl group at the 4′ position. When used as siRNA, the oligonucleic acid analog exhibits superior biological stability and target gene expression inhibiting activity. The oligonucleic acid analog can be used in antisense methods, ribozyme methods, and decoy methods, etc., can be used as a nucleic acid aptamer, and can also be used as a nucleic acid probe or molecular beacon, etc., or in genetic diagnostics, etc. | 01-21-2016 |
20160060228 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND - This invention is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions. | 03-03-2016 |
20160200744 | CONVENIENT PROCESS FOR THE PREPARATION OF STATINS | 07-14-2016 |
20170233414 | DERIVATIVES OF BODIPY | 08-17-2017 |